Logo

AVXL

Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp. • NASDAQ
$3.83 ▼ -0.78% (-0.03)
Market Cap $342.20 M
52w High $14.44
52w Low $2.86
Dividend Yield 0%
P/E -7.09
Volume 1.68M
Outstanding Shares 89.35M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $14.459M ▲ $-13.243M ▼ 0% $-0.16 ▼ $-13.37M ▼
Q2-2025 $0 $12.513M ▼ $-11.196M ▲ 0% $-0.13 ▲ $1.125M ▲
Q1-2025 $0 $13.592M ▼ $-12.111M ▼ 0% $-0.14 $-11.466M ▲
Q4-2024 $0 $14.336M ▼ $-11.62M ▲ 0% $-0.14 $-34.019M ▼
Q3-2024 $0 $14.729M $-12.214M 0% $-0.14 $-12.268M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $101.164M ▼ $102.432M ▼ $11.474M ▼ $90.958M ▼
Q2-2025 $115.771M ▼ $117.139M ▼ $17.381M ▲ $99.758M ▼
Q1-2025 $120.775M ▼ $124.043M ▼ $13.128M ▼ $110.915M ▼
Q4-2024 $132.187M ▼ $135.567M ▼ $15.304M ▲ $120.263M ▼
Q3-2024 $138.756M $141.535M $11.754M $129.781M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-13.243M ▼ $-12.464M ▼ $0 $-2.143M ▼ $-14.607M ▼ $-12.464M ▼
Q2-2025 $-11.196M ▲ $-5.856M ▲ $0 $852K ▲ $-5.004M ▲ $-5.856M ▲
Q1-2025 $-12.111M ▼ $-12.12M ▼ $0 $708K ▲ $-11.412M ▼ $-12.12M ▼
Q4-2024 $-11.62M ▲ $-6.658M ▼ $0 $89K ▼ $-6.569M ▼ $-6.658M ▼
Q3-2024 $-12.214M $-5.18M $0 $4.55M $-630K $-5.18M

Five-Year Company Overview

Income Statement

Income Statement Anavex is still a pure research-stage biotech. It has essentially no product sales yet, so its income statement is driven almost entirely by research and development and overhead costs. Losses have been steady over the last several years rather than exploding, which suggests spending is relatively controlled, but the company is consistently in the red. The lack of revenue means future results will hinge heavily on whether any of its drug candidates reach approval and commercialization, or it signs meaningful partnership deals.

Balance Sheet

Balance Sheet The balance sheet is simple and fairly clean. Most assets are held as cash or near-cash, and there is effectively no financial debt, which reduces financing risk and interest burdens. Equity has ticked down over time as losses accumulate, which is normal for a small biotech still in development. Overall, the company looks funded for continued clinical work in the near term, but longer-term, it will likely need new capital or partnerships unless it begins to generate revenue.

Cash Flow

Cash Flow Cash flow is consistently negative, reflecting ongoing spending on clinical trials, staff, and operations without offsetting revenue. Cash burn appears relatively stable rather than rapidly accelerating, and there is little to no spending on physical assets or facilities, keeping capital needs mostly limited to R&D and corporate costs. Still, as is typical for clinical-stage biotech, the business model is heavily dependent on external financing until a product reaches market or a partner steps in to share costs.

Competitive Edge

Competitive Edge Anavex operates in one of the toughest and most competitive areas of healthcare: diseases of the brain and nervous system. Its core edge is a differentiated scientific approach focused on the sigma-1 receptor, rather than the more crowded amyloid and tau targets. This gives it a niche position and could be an advantage if its mechanism continues to show benefit where others struggle. The company has layered on patent protection, orphan designations, and a broad set of potential indications, which all help its positioning. However, it is still small compared to large pharma rivals and faces intense competition for patients, trial sites, regulatory attention, and eventual market share if its drugs are approved.

Innovation and R&D

Innovation and R&D Innovation is the heart of Anavex. The SIGMACEPTOR platform and sigma-1 receptor focus provide a clear scientific identity and a potentially disease-modifying approach to neurodegenerative and neurodevelopmental disorders. The pipeline is concentrated but diversified across several conditions, with one lead candidate in later-stage development and others progressing through mid- and early-stage trials. The company is also leaning into precision medicine, using genetic markers to identify patients more likely to respond, which could improve trial outcomes and clinical use if validated. Overall, R&D is high-risk but thoughtfully focused, with a clear scientific thesis and multiple shots on goal within the same biology.

Summary

Anavex is a classic high-risk, high-uncertainty clinical-stage biotech: no commercial revenue, steady operating losses, and a reliance on its cash reserves and capital markets to fund progress. The balance sheet is simple and relatively unburdened by debt, and cash burn appears measured rather than extreme, which supports continued development in the near term. The real story is strategic and scientific rather than financial: a differentiated mechanism, a growing intellectual property base, and a pipeline addressing major unmet needs in Alzheimer’s, Parkinson’s-related dementia, Rett syndrome, and other CNS disorders. The upside case depends heavily on upcoming regulatory and clinical milestones for its lead programs and its ability to translate promising trial signals into approvals and, eventually, sustainable revenue. Until then, the company remains in an inherently binary phase, where scientific and regulatory outcomes will matter far more than recent historical financials.

NEWS

November 26, 2025 · 7:30 AM UTC

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Read more

November 25, 2025 · 7:30 AM UTC

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Read more

November 19, 2025 · 7:30 AM UTC

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Read more

November 18, 2025 · 7:56 PM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Read more

November 18, 2025 · 7:30 AM UTC

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Read more